Proteomics in gerontology: Current applications and future aspects - A mini-review

Gerontology

Volumn 55, Issue 2, 2009, Pages 123-137

  Schiffer, E ^a   Mischak, H ^a   Zimmerli, L U ^b  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Coronary artery disease; Diabetic nephropathy; Neoplasia; Proteomics

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ALBUMIN; ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; CALRETICULIN; CANDESARTAN; CATECHOL METHYLTRANSFERASE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DNA; FATTY ACID BINDING PROTEIN; GAMMA SYNUCLEIN; GELATINASE B; GLUTATHIONE TRANSFERASE; GROWTH DIFFERENTIATION FACTOR 15; KERATIN; POLYPEPTIDE; PROSTATE SPECIFIC ANTIGEN; PROTEOME;

AGED; AGING; ANALYTIC METHOD; BIOINFORMATICS; BLADDER CANCER; BLOOD ANALYSIS; BREAST CANCER; CANCER SCREENING; CAPILLARY ELECTROPHORESIS; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DNA DAMAGE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MOLECULE; NEOPLASM; OPTIMAL DRUG DOSE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEOMICS; SHORT SURVEY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT OUTCOME; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINALYSIS; UROGENITAL TRACT CANCER; WESTERN BLOTTING;

AGED; AGING; BIOLOGICAL MARKERS; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHIES; FEMALE; GERIATRICS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEOME; PROTEOMICS; URINARY BLADDER NEOPLASMS;

EID: 62249105158     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000191653     Document Type: Short Survey

References (86)

1. Ginsburg GS, Haga SB: Translating genomic biomarkers into clinically useful diagnostics. Expert Rev Mol Diagn 2006;6:179-191.
2. Lindon JC, Holmes E, Nicholson JK: Metabonomics and its role in drug development and disease diagnosis. Expert Rev Mol Diagn 2004;4:189-199.
3. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes JS, Kapp EA, Moritz RL, Chan DW, Rai AJ, Admon A, Aebersold R, Eng J, Hancock WS, Hefta SA, Meyer H, Paik YK, Yoo JS, Ping P, Pounds J, Adkins J, Qian X, Wang R, Wasinger V, Wu CY, Zhao X, Zeng R, Archakov A, Tsugita A, Beer I, Pandey A, Pisano M, Andrews P, Tammen H, Speicher DW, Hanash SM: Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3,020 proteins and a publicly-available database. Proteomics 2005;5:3226-3245.
4. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P: Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65:323-332.
5. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF: Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006;7:230-240.
6. Fiedler GM, Baumann S, Leichtle A, Oltmann A, Kase J, Thiery J, Ceglarek U: Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2007;53:421-428.
7. Mischak H, Apweiler R, Banks RE, Conaway M, Coon JJ, Dominizak A, Ehrich JH, Fliser D, Girolami M, Hermjakob H, Hochstrasser DF, Jankowski V, Julian BA, Kolch W, Massy Z, Neususs C, Novak J, Peter K, Rossing K, Schanstra JP, Semmes OJ, Theodorescu D, Thongboonkerd V, Weissinger EM, Van Eyk JE, Yamamoto T: Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007;1:148-156.
8. Kolch W, Neususs C, Pelzing M, Mischak H: Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005;24:959-977.
9. Zürbig P, Renfrow MB, Schiffer E, Novak J, Walden M, Wittke S, Just I, Pelzing M, Neususs C, Theodorescu D, Root C, Ross M, Mischak H: Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006;27:2111-2125.
10. Annesley TM: Ion suppression in mass spectrometry. Clin Chem 2003;49:1041-1044.
11. Patterson SD, Aebersold R: Mass spectrometric approaches for the identification of gel-separated proteins. Electrophoresis 1995;16:1791-1814.
12. Wu TL: Two-dimensional difference gel electrophoresis. Methods Mol Biol 2006;328:71-95.
13. Issaq HJ: The role of separation science in proteomics research. Electrophoresis 2001;22:3629-3638.
14. Munro NP, Cairns DA, Clarke P, Rogers M, Stanley AJ, Barrett JH, Harnden P, Thompson D, Eardley I, Banks RE, Knowles MA: Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 2006;119:2642-2650.
15. Zerefos P, Prados J, Kossida S, Kalousis A, Vlahou A: Sample preparation and bioinformatics in MALDI profiling of urinary proteins. J Chromatogr B Analyt Technol Biomed Life Sci 2007;853:20-30.
16. Najam-ul-Haq M, Rainer M, Trojer L, Feuerstein I, Vallant RM, Huck CW, Bakry R, Bonn GK: Alternative profiling platform based on MELDI and its applicability in clinical proteomics. Expert Rev Proteomics 2007;4:447-452.
17. Qian WJ, Jacobs JM, Liu T, Camp DG, Smith RD: Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics 2006;5:1727-1744.
18. Kislinger T, Gramolini AO, Maclennan DH, Emili A: Multidimensional protein identification technology (MudPIT): technical overview of a profiling method optimized for the comprehensive proteomic investigation of normal and diseased heart tissue. J Am Soc Mass Spectrom 2005;16:1207-1220.
19. Soldi M, Sarto C, Valsecchi C, Magni F, Proserpio V, Ticozzi D, Mocarelli P: Proteome profile of human urine with two-dimensional liquid phase fractionation. Proteomics 2005;5:2641-2647.
20. Bakry R, Huck CW, Najam-ul-Haq M, Rainer M, Bonn GK: Recent advances in capillary electrophoresis for biomarker discovery. J Sep Sci 2007;30:192-201.
21. Wu R, Hu L, Wang F, Ye M, Zou H: Recent development of monolithic stationary phases with emphasis on microscale chromatographic separation. J Chromatogr A 2008;1184:369-392.
22. Schmitt-Kopplin P, Frommberger M: Capillary electrophoresis-mass spectrometry: 15 years of developments and applications. Electrophoresis 2003;24:3837-3867.
23. Hernandez-Borges J, Neususs C, Cifuentes A, Pelzing M: On-line capillary electrophoresis-mass spectrometry for the analysis of biomolecules. Electrophoresis 2004;25:2257-2281.
24. Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, Ross M, Eltze E, Bettendorf O, Wulfing C, Semjonow A: Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005;26:2797-2808.
25. Kozarova A, Petrinac S, Ali A, Hudson JW: Array of informatics: applications in modern research. J Proteome Res 2006;5:1051-1059.
26. Shaw J, Rowlinson R, Nickson J, Stone T, Sweet A, Williams K, Tonge R: Evaluation of saturation labelling two-dimensional difference gel electrophoresis fluorescent dyes. Proteomics 2003;3:1181-1195.
27. Wang W, Zhou H, Lin H, Roy S, Shaler TA, Hill LR, Norton S, Kumar P, Anderle M, Becker CH: Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal Chem 2003;75:4818-4826.
28. Girolami M, Mischak H, Krebs R: Analysis of complex, multidimensional datasets. Drug Discov Today 2007;3:12-19.
29. Girolami M, Rogers S: Variational Bayesian multinomial probit regression with Gaussian process priors. Neural Comput 2006;18:1790-1817.
30. Burges CJC: A tutorial on support vector machines for pattern recognition. Knowledge Discovery Data Mining 1998;2:121-167.
31. Rasmussen CE, Williams CKI: Gaussian Processes for Machine Learning. Boston, MIT Press, 2006.
32. Jiang H, Schiffer E, Song Z, Wang J, Zürbig P, Thedieck K, Moes S, Bantel H, Saal N, Jantos J, Brecht M, Jeno P, Hall MN, Hager K, Manns MP, Hecker H, Ganser A, Dohner K, Bartke A, Meissner C, Mischak H, Ju Z, Rudolph KL: Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci USA 2008;105:11299-11304.
33. Orgel LE: Ageing of clones of mammalian cells. Nature 1973;243:441-445.
34. Sharma K, Lee S, Han S, Lee S, Francos B, McCue P, Wassell R, Shaw MA, Ramachandra Rao SP: Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005;5:2648-2655.
35. Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, Knueppel S, Haller H, Fliser D: Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond) 2004;107:485-495.
36. Thongboonkerd V, McLeish KR, Arthur JM, Klein JB: Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 2002;62:1461-1469.
37. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M: The human urinary proteome contains more than 1,500 proteins including a large proportion of membranes proteins. Genome Biol 2006;7:R80.
38. Coon JJ, Zürbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, Frommberger M, Golovko I, Good DM, Herget-Rosenthal S, Jankowski J, Julian BA, Kellmann M, Kolch W, Massy Z, Novak J, Rossing K, Schanstra JP, Schiffer E, Theodorescu D, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P: CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008;2:964-973.
39. Haubitz M, Fliser D, Rupprecht H, Floege J, Haller H, Rossing K, Walden M, Wittke S, Mischak H: Defining renal diseases based on proteome analysis. Nephrol Dial Transplant 2005;20:V20.
40. Julian BA, Wittke S, Novak J, Good DM, Coon JJ, Kellmann M, Zürbig P, Schiffer E, Haubitz M, Moldoveanu Z, Calcatera SM, Wyatt RJ, Sykora J, Sladkova E, Hes O, Mischak H, McGuire BM: Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007;28:4469-4483.
41. Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P: Proteomic discovery and validation of urinary biomarkers for diabetes and chronic renal disease. J Am Soc Nephrol 2008; in press.
42. Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillmann M, Kaiser T: Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005;68:193-205.
43. Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH: Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care 2003;26:150-155.
44. Verhave JC, Hillege HL, Burgerhof JG, Gansevoort RT, de Zeeuw D, de Jong PE; PREVEND Study Group: The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005;67:1967-1973.
45. Sung HJ, Ryang YS, Jang SW, Lee CW, Han KH, Ko J: Proteomic analysis of differential protein expression in atherosclerosis. Biomarkers 2006;11:279-290.
46. You SA, Archacki SR, Angheloiu G, Moravec CS, Rao S, Kinter M, Topol EJ, Wang Q: Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genomics 2003;13:25-30.
47. Duran MC, Martin-Ventura JL, Mas S, Barderas MG, Darde VM, Jensen ON, Egido J, Vivanco F: Characterization of the human atheroma plaque secretome by proteomic analysis. Methods Mol Biol 2007;357:141-150.
48. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-756.
49. Zimmerli LU, Schiffer E, Zürbig P, Kellmann M, Mouls L, Pitt A, Coon JJ, Schmiederer RE, Mischak H, Peter K, Kolch W, Delles C, Dominiczak AF: Urinary proteomics biomarkers in coronary artery disease. Mol Cell Proteomics 2008;7:290-298.
50. Berhane BT, Zong C, Liem DA, Huang A, Le S, Edmondson RD, Jones RC, Qiao X, Whitelegge JP, Ping P, Vondriska TM: Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 2005;5:3520-3530.
51. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
52. Presti JC Jr: Prostate cancer: assessment of risk using digital rectal examination, tumor grade, prostate-specific antigen, and systematic biopsy. Radiol Clin North Am 2000;38:49-58.
53. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, Webber D, Kinahan T, Sadar M, Gleave ME, Vielkind J: Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 2004;64:5929-5933.
54. Liu AY, Zhang H, Sorensen CM, Diamond DL: Analysis of prostate cancer by proteomics using tissue specimens. J Urol 2005;173:73-78.
55. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-3614.
56. Rehman I, Azzouzi AR, Catto JW, Allen S, Cross SS, Feeley K, Meuth M, Hamdy FC: Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004;64:1238-1243.
57. M'koma AE, Blum DL, Norris JL, Koyama T, Billheimer D, Motley S, Ghiassi M, Ferdowsi N, Bhowmick I, Chang SS, Fowke JH, Caprioli RM, Bhowmick NA: Detection of preneoplastic and neoplastic prostate disease by MADI profiling of urine. Biochem Biophys Res Commun 2006;353:829-834.
58. Wittke S, Schiffer E, Bauer HW: Kapillarelektrophorese gekoppelte Massenspektrometrie zur Proteomanalyse als innovative diagnostische Methode bei Prostata- und Blasenkrebs. Urologe A 2007;46:733-739.
59. Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ, Bahnson RR: Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996;56:1690-1694.
60. Konety BR, Nguyen TS, Brenes G, Sholder A, Lewis N, Bastacky S, Potter DM, Getzenberg RH: Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000;164:634-639.
61. Nielsen ME, Gonzalgo ML, Schoenberg MP, Getzenberg RH: Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. World J Urol 2006;24:499-508.
62. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH: Highly specific urine-based marker of bladder cancer. Urology 2005;66:1256-1260.
63. Rasmussen HH, Orntoft TF, Wolf H, Celis JE: Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J Urol 1996;155:2113-2119.
64. Celis JE, Ostergaard M, Basse B, Celis A, Lauridsen JB, Ratz GP, Andersen I, Hein B, Wolf H, Orntoft TF, Rasmussen HH: Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 1996;56:4782-4790.
65. Ohlsson G, Moreira JM, Gromov P, Sauter G, Celis JE: Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 2005;4:570-581.
66. Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M, Yoshiki T: Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gammasynuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004;95:955-961.
67. Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y, Yoshiki T: Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 2004;50:857-866.
68. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright JG Jr: Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-1502.
69. Holterman DA, Diaz JI, Blackmore PF, Davis JW, Schellhammer PF, Semmes OJ, Vlahou A: Overexpression of alpha-defensin is associated with bladder cancer invasiveness. Urol Oncol 2006;24:97-108.
70. Mueller J, von Eggeling F, Driesch D, Schubert J, Melle C, Junker K: ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol 2005;47:885-893.
71. Vlahou A, Giannopoulos A, Gregory BW, Manousakas T, Kondylis FI, Wilson LL, Schellhammer PF, Wright GL Jr, Semmes OJ: Protein profiling in urine for the diagnosis of bladder cancer. Clin Chem 2004;50:1438-1441.
72. Zhang YF, Wu DL, Guan M, Liu WW, Wu Z, Chen YM, Zhang WZ, Lu Y: Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin Biochem 2004;37:772-779.
73. Liu W, Guan M, Wu D, Zhang Y, Wu Z, Xu M, Lu Y: Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 2005;47:456-462.
74. Bertucci F, Birnbaum D, Goncalves A: Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 2006;5:1772-1786.
75. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, Fiche M, Figueiro P, Maisongrosse V, Ledoussal V, Martinez PJ, Udvarhely N, El MG, Ginestier C, Geneix J, Charafe-Jauffret E, Xerri L, Eisinger F, Birnbaum D, Sobol H: Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005;207:260-268.
76. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F: Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005;65:767-779.
77. Moreira JM, Ohlsson G, Rank FE, Celis JE: Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol Cell Proteomics 2005;4:555-569.
78. Moreira JM, Gromov P, Celis JE: Expression of the tumor suppressor protein 14-3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Mol Cell Proteomics 2004;3:410-419.
79. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-1304.
80. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, Perry RR, Wright GL Jr, Semmes OJ: A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003;4:203-209.
81. Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR, Laronga C: Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 2004;11:907-914.
82. Hu Y, Zhang S, Yu J, Liu J, Zheng S: SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 2005;14:250-255.
83. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF, III: Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001;17:301-307.
84. Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC: Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 2002;86:1440-1443.
85. Noble J, Dua RS, Locke I, Eeles R, Gui GP, Isacke CM: Proteomic analysis of nipple aspirate fluid throughout the menstrual cycle in healthy pre-menopausal women. Breast Cancer Res Treat 2007;104:191-196.
86. Streckfus CF, Mayorga-Wark O, Arreola D, Edwards C, Bigler L, Dubinsky WP: Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Invest 2008;26:159-167.